Physician profile
Olga Segal
NPI 1518117316
$1,629.89
in general payments reported to CMS, 2019-2025
15 companies · $95.32 in 2025
The $95.32 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $74.41 · 2021: $336 · 2022: $376 · 2023: $129 · 2024: $144 · 2025: $95.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $448.79 | 2021-2025 | |
| Neuropace, INC. | $298.05 | 2019-2021 | |
| Ucb, INC. | $211.13 | 2019-2023 | Briviact, Nayzilam, Fintepla |
| Sunovion Pharmaceuticals INC. | $136.13 | 2019-2021 | |
| Neurelis, INC. | $115.26 | 2022-2025 | Valtoco |
| Greenwich Biosciences, INC. | $99.84 | 2019 | |
| Livanova USA, INC. | $87.75 | 2020-2022 | |
| Biogen, INC. | $67.19 | 2019 | |
| Celgene Corporation | $32.96 | 2023 | Zeposia |
| Aquestive Therapeutics, INC. | $30.55 | 2019 | |
| Jazz Pharmaceuticals INC. | $29.20 | 2022-2024 | |
| Eisai INC. | $26.78 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $18.25 | 2020 | |
| Pfizer INC. | $16.60 | 2024 | |
| Aprecia Pharmaceuticals, LLC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Segal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.